Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 6/20 | 0.36 |
| ▸ | CPT2 | P23786 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.35 |
| ▸ | ROS1 | P08922 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580754 | 0.87 | GABRA1 (0.34) | CPT1ACPT2SCN9ACPT1BPIN1 | |
| SCHEMBL13031207 | 0.85 | SCN9A (0.38) | ADORA2AADORA1SCN9ASCN10AROS1 | |
| SCHEMBL3579069 | 0.83 | GABRA1 (0.34) | CPT1ACPT2CPT1B | |
| SCHEMBL3589661 | 0.82 | TLR8 (0.40) | CPT1ACPT2 | |
| SCHEMBL3586267 | 0.81 | CXCR3 (0.42) | — | |
| SCHEMBL3593480 | 0.80 | CPT1A (0.35) | CPT1ACPT2CPT1B | |
| SCHEMBL3578439 | 0.80 | CXCR3 (0.40) | CPT1ACPT2 | |
| SCHEMBL3587157 | 0.80 | CXCR3 (0.41) | — | |
| SCHEMBL3589593 | 0.79 | LMNA (0.40) | CPT1ACPT2 | |
| SCHEMBL3592264 | 0.79 | CPT1A (0.33) | CPT1ACPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-1962605-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | USP30 3821/4885ADORA2A 72/4885ADORA1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.